Free tool
FAERS Monitor: Xocova
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220442 or its brand name (Xocova, Ensitrelvir). Reports on generic versions are filed under their own applications.
Reports
18
Serious
8
44% of reports
Hospitalization
6
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction8
- product use in unapproved indication7
- drug half-life increased4
- immunosuppressant drug level increased4
- covid-193
- covid-19 pneumonia3
- drug clearance decreased3
- blood creatinine increased2
- drug ineffective for unapproved indication2
- drug level increased2
- off label use2
- pneumonia2
- accidental exposure to product1
- anti-neutrophil cytoplasmic antibody positive vasculitis1
- cytokine release syndrome1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 8 |
| 2025 | 6 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug half-life increasedSignal | 4 | 42533.6 | 17567.4 | 125,683 |
| drug clearance decreasedSignal | 3 | 2691.0 | 956.4 | 5,589 |
| immunosuppressant drug level increasedSignal | 4 | 1416.9 | 596.6 | 4,328 |
| anti-neutrophil cytoplasmic antibody positive vasculitis | 1 | 473.0 | 70.4 | 117 |
| covid-19 pneumoniaSignal | 3 | 297.0 | 105.7 | 614 |
| drug level increased | 2 | 141.2 | 38.2 | 156 |
| drug interactionSignal | 8 | 58.9 | 35.2 | 402 |
| cytokine release syndrome | 1 | 58.3 | 8.7 | 14 |
| drug ineffective for unapproved indication | 2 | 42.6 | 11.5 | 45 |
| blood creatinine increased | 2 | 35.8 | 9.7 | 37 |
| product use in unapproved indicationSignal | 7 | 33.0 | 18.5 | 189 |
| covid-19Signal | 3 | 20.0 | 7.1 | 37 |
| accidental exposure to product | 1 | 11.3 | 1.7 | 2 |
| pneumonia | 2 | 7.2 | 2.0 | 5 |
| off label use | 2 | 2.7 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.